FMP
Enter
API Tools
Extras
Protagenic Therapeutics, Inc.
PTIX
NASDAQ
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
0.3 USD
0.0412 (13.73%)
Terminal Value
Growth In Perpetuity Method
Long Term Growth Rate
Wacc
7.89
Free Cash Flow T1
548.39M
Terminal Value
7.42B
Present Terminal Value
5.08B
